Japan India virus covid-19 president patient Japan India

Covid-19: Glenmark begins phase 3 of clinical trials on antiviral Favipiravir

Reading now: 127
www.livemint.com

Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so.

It had obtained approval from the Drug Controller General of India (DCGI) in late April. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd in Japan, a subsidiary of Fujifilm Corporation. "Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study.

Glenmark estimates study completion by July or August," it said in a statement on Tuesday. Glenmark has successfully developed the active pharma ingredient (API) and the formulations for the product through its in-house R&D team.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA